Hirohiko Shibayama
12PUBLICATIONS
57CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Mar 29, 2024
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).Hirohiko Shibayama, Mitsuhiro Itagaki, Hiroshi Handa
|Mar 01, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.Yasunori Kogure, Hiroshi Handa, Yuta Ito
|Mar 25, 2021
High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.Hideaki Saito, Hiroaki Miyoshi, Hirohiko Shibayama
|Mar 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.Thierry Facon, Christopher P Venner, Nizar J Bahlis
|Mar 17, 2021
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi
Pageof 2
Frequent Collaborators
2 joint publications
Koji Izutsu
2 joint publications
Masaki Iino
1 joint publications
Noriko Fukuhara
1 joint publications
Tomoko Yanai
1 joint publications
Kazunori Shibuya
1 joint publications
Tetsuhisa Kitamura
1 joint publications
Jun Toda
1 joint publications
Michiko Ichii
1 joint publications
Daisuke Okuzaki
1 joint publications
Ryuta Muromoto
